Immunotherapy with chemotherapy for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Immune system & allergy clinical trials.
This trial tests whether adding an immunotherapy drug (which helps your immune system fight cancer) to standard chemotherapy can improve outcomes for people with advanced nasopharyngeal cancer (a type of cancer in the upper throat). If you qualify, you would receive this combination treatment as your first therapy for this stage of disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with locally advanced nasopharyngeal cancer (stage III or IV).
- You are able to carry out daily activities with minimal help (ECOG score 0-1).
- Your major organs (blood, liver, kidneys) are working well enough for treatment.
- You are not pregnant or breastfeeding and are willing to use birth control during the study.
- You have not had another cancer in the last 5 years (except for some skin cancers or early cervical cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (sintilimab), a targeted therapy (bevacizumab), and chemotherapy—for patients with high-risk, locally advanced nasopharyngeal cancer that has not spread to distant organs. The goal is to see if adding these drugs to standard chemoradiation improves outcomes.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people whose nasopharyngeal cancer has come back or spread. It is for those who haven't yet received other treatments for this advanced stage.
This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.
Hear when a new Locally Advanced Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.